Iradimed Co
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +51.2% | +5.5% | +4.9% | +24.2% | +37.7% | +6.5% | +16.6% | +3.2% | +7.8% | +6.7% | +10.6% | |
| – | +53.2% | +0.6% | +2.7% | +26.9% | +32.4% | +8.1% | +19.6% | +1.6% | -1.9% | -1.0% | +7.9% | |
| – | +104.9% | -8.5% | +2.8% | +53.9% | +55.1% | +15.1% | +23.8% | -6.5% | -14.1% | +5.0% | -2.1% | |
| – | +55.3% | -4.8% | +2.6% | +30.5% | +34.5% | +12.4% | +20.2% | -7.3% | -14.1% | +5.0% | -2.1% | |
| – | +97.1% | -2.3% | +0.1% | +11.4% | +73.2% | -37.3% | +12.3% | +158.4% | -7.9% | -13.6% | +29.5% | |
| – | +12.1% | +63.1% | +8.3% | -3.6% | -10.3% | +8.0% | +9.3% | +24.9% | +138.8% | -18.9% | +11.7% | |
| – | +13.9% | +60.8% | +28.3% | +0.0% | +9.9% | +3.2% | +114.7% | -47.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -30.0% | +423.4% | -3.6% | -6.0% | +3.3% | +11.7% | +16.4% | +85.0% | +21.7% | +23.0% | +9.2% | |
| – | +36.9% | +60.2% | +14.6% | +6.8% | +72.5% | -13.6% | +10.6% | +10.6% | +75.1% | -44.5% | +23.0% | |
| – | +27.2% | +26.5% | +11.4% | +15.0% | +24.9% | -16.1% | +38.8% | +25.4% | +90.9% | -47.9% | +19.6% | |
| – | -53.4% | +4,420.7% | +22.2% | -92.2% | +81.1% | +6.2% | +8.2% | +6.1% | +45.8% | -64.2% | – | |
| – | +59.8% | +11.5% | -41.4% | +17.6% | +28.6% | -33.9% | +19.2% | +129.8% | +3.2% | +2.1% | -4.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +52.9% | -0.1% | +3.3% | +27.4% | +32.4% | +10.6% | +17.6% | +2.1% | -3.1% | +21.6% | +9.0% | |
| – | +146.9% | +57.0% | +2.4% | +31.0% | +36.1% | +3.8% | +24.8% | +0.6% | -8.5% | +31.3% | +13.1% | |
| – | +22.9% | -4.5% | -2.2% | +3.3% | +1.4% | +1.3% | +1.2% | +0.4% | +0.7% | +0.5% | +0.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.